- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03535298
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham University Hospitals NHS Trust, Queens Medical Centre
-
-
England
-
Coventry, England, United Kingdom, CV2 2DX
- University Hospitals Coventry and Warwickshire
-
Leeds, England, United Kingdom, LS1 3EX
- The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary
-
Leicester, England, United Kingdom, LE1 5WW
- University Hospitals Leicester
-
London, England, United Kingdom, W6 8RF
- Imperial College Healthcare NHS Trust, Charing Cross Hospital
-
London, England, United Kingdom, WC1N 3BG
- University College London Hospitals NHS Foundation Trust, University College Hospital
-
Manchester, England, United Kingdom, M6 8HD
- Salford Royal NHS Foundation Trust, Salford Hospital
-
Oxford, England, United Kingdom, OX3 9DU
- Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital
-
Plymouth, England, United Kingdom, PL6 8DH
- University Hospitals Plymouth NHS Trust, Derriford Hospital
-
Sheffield, England, United Kingdom, S5 7AT
- Sheffield Teaching Hospitals
-
Stoke, England, United Kingdom, ST4 6QG
- University Hospitals of North Midlands
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH16 4SA
- Royal Infirmary of Edinburgh
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF14 4XW
- Cardiff and Vale University Local Health Board, University Hospital of Wales
-
Newport, Wales, United Kingdom, NP19 0BH
- Aneurin Bevan Local Health Board Headquarters, Royal Gwent Hospital
-
Swansea, Wales, United Kingdom, SA6 6NL
- Swansea Bay University Local Health Board, Morriston Hospital
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado-Anschutz Medical Campus
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Cleveland Clinic Lou Ruvo Center for Brain health
-
-
New York
-
Buffalo, New York, United States, 14202
- University of Buffalo
-
Rochester, New York, United States, 14642
- University Rochester Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Columbus, Ohio, United States, 43214
- Ohio Health
-
-
Texas
-
Austin, Texas, United States, 78712
- UT-Austin
-
Houston, Texas, United States, 77030
- Baylor College of Medicine, Houston
-
Houston, Texas, United States, 77030
- UTHealth-Houston
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
Richmond, Virginia, United States, 23284
- Virginia Commonwealth University
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- University of Wisconsin-Madison
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women aged 18 to 60 years.
- Established diagnosis of MS, as defined by the 2017 revision of McDonald Diagnostic Criteria (99).
- RRMS disease course as defined by the 2013 revisions of the MS clinical course definition (4).
- Participants must have evidence of active disease based on: one or more MS relapses within the last 18 months prior to screening visit or radiological evidence of MS activity (≥2 new T2 lesions within the last 12 months from screening [compared to a previous recent MRI within 18 months of screening] or ≥1 GdE demonstrated on brain or spinal cord MRI performed within the last 12 months of screening).
- Participants must be ambulatory with disease onset ≤ 5 years and treatment-naïve (i.e., no MS DMT at any time in the past).
- Participants must be eligible to receive at least one form of DMT within each treatment arm.
- EDSS at Baseline visit ≤ 6.5
Exclusion Criteria:
- Participants with contraindications to all forms of DMT in either of the treatment arms.
- Participants must never have received any of the following medications: natalizumab, alemtuzumab, ocrelizumab, rituximab, ofatumumab, cladribine, siponimod, interferon beta-1a, interferon beta-1b, pegylated interferon beta-1a, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, daclizumab, mitoxantrone, diroximel fumarate, ozanimod, monomethyl fumarate, ponesimod.
- Participants must have not received any of the following medications, for reasons other than MS, in the last 12 months: cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, leflunomide, laquinimod, atacicept, other monoclonal antibodies.
- Participants with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study
- Participants unable to provide informed consent.
- Contraindication or inability to undergo MRI with Gd due to metal or metal implants, allergy to Gd contrast, claustrophobia, pain, spasticity, or excessive movement related to tremor.
- Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that, in the opinion of the PI, is likely to affect the participant's ability to comply with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EHT: Early Highly-effective
Participants randomized to the "EHT: Early Highly-effective" arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment. Interventions: one of the highly effective MS therapies The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group. |
Highly Effective MS Therapy group of medications
Other Names:
|
Experimental: ESC: Escalation
Participants randomized to the "ESC: Escalation" arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment. Interventions: one of the MS therapies NOT in the highly effective group The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group. |
Escalation MS Therapy group of medications
Other Names:
|
No Intervention: OBS: Observational
Participants will not be restricted to a group of MS therapies. Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain volume loss, baseline to month 36
Time Frame: Baseline to 36 months
|
To determine whether an EHT approach to DMT, defined as use of one of four monoclonal antibodies (alemtuzumab, natalizumab, rituximab, or ocrelizumab) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Baseline to Month 36.
|
Baseline to 36 months
|
EDSS+, month 48 to month 72
Time Frame: 48 months to 72 months
|
To determine whether an EHT approach to DMT, defined as use of one of six monoclonal antibodies (alemtuzumab, natalizumab, rituximab, ocrelizumab, ofatumumab, ublituximab) as first-line therapy, is more effective than an escalation of treatment approach in reducing time to reach a multidimensional composite comprised of EDSS+ worsening.
EDSS+ worsening will be defined as worsening on ⩾ 1 of the 3 components: EDSS, 9HPT, or T25FW, which is confirmed at another visit after 12 months.
EDSS worsening will be defined as a ⩾1.0-point increase from a baseline score of ⩽5.5 or a ⩾0.5-point increase from a baseline score of ⩾6.0.
T25FW and 9HPT worsening will be defined as ⩾20% worsening from baseline.
|
48 months to 72 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain volume loss, month 6 to month 36
Time Frame: Month 6 to month 36
|
To determine whether an EHT approach to DMT, defined as use of one of four monoclonal antibodies (alemtuzumab, natalizumab, rituximab, or ocrelizumab) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Month 6 to Month 36.
|
Month 6 to month 36
|
Proportion of participants with progression
Time Frame: Baseline to 36 months
|
Proportion of participants with a multidimensional composite comprised of EDSS progression (>1.5 points for those with EDSS of 0 at Baseline, ≥1.0 for those with EDSS of 0.5-5.0 at Baseline, and >0.5 points for those with EDSS above 5.0 at Baseline), 20% change in MSFC-4 subcomponents (T25FW, 9HPT), 10% in SDMT or, 1 line change in LCLA confirmed over 12 months.
|
Baseline to 36 months
|
Change in MSIS-29, baseline to 36 months
Time Frame: Baseline to 36 months
|
Change in MSIS-29 responses from participants
|
Baseline to 36 months
|
Change in Neuro-QOL, baseline to 36 months
Time Frame: Baseline to 36 months
|
11 subscales, each is scored separately, there is no composite score Physical Domains: Upper Extremity Function (Fine Motor, ADL): Higher scores indicate: Better Functioning Lower Extremity Function (Mobility): Higher scores indicate: Better Functioning Fatigue: Higher scores indicate: Worse Functioning Sleep Disturbance: Higher scores indicate: Worse Functioning Mental Domains: Cognition Function: Higher scores indicate: Better Functioning Stigma: Higher scores indicate: Worse Functioning Anxiety: Higher scores indicate: Worse Functioning Depression: Higher scores indicate: Worse Functioning Positive Affect and Well -being: Higher scores indicate: Better Functioning Social Domains: Ability to Participate in Social Roles and Activities: Higher scores indicate: Better Functioning Satisfaction with Social Roles and Activities: Higher scores indicate: Better Functioning |
Baseline to 36 months
|
Time to reach SPMS, month 48 to month 72
Time Frame: 48 months to 72 months
|
To determine the efficacy of an EHT approach as compared to an escalation approach as reflected by the following:
|
48 months to 72 months
|
Efficacy difference between EHT and ESC, month 48 to month 72
Time Frame: 48 months to 72 months
|
To determine the efficacy of an EHT approach as compared to an escalation approach as reflected in the following patient-reported outcomes:
|
48 months to 72 months
|
Safety difference between EHT and ESC, month 48 to month 72
Time Frame: 48 months to 72 months
|
To determine the safety of an EHT approach as compared to an escalation approach as reflected in the following:
|
48 months to 72 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Ontaneda, MD, MSc, The Cleveland Clinic
- Principal Investigator: Nikos Evangelou, MD, DPhil, University of Nottingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Adjuvants, Immunologic
- Sphingosine 1 Phosphate Receptor Modulators
- Interferons
- Ofatumumab
- Ocrelizumab
- Natalizumab
- Cladribine
- Fingolimod Hydrochloride
- Interferon-beta
- Ozanimod
- Alemtuzumab
- Glatiramer Acetate
- (T,G)-A-L
- Dimethyl Fumarate
- Siponimod
- Teriflunomide
- Ponesimod
Other Study ID Numbers
- CCF 18-326
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenWithdrawn
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
Clinical Trials on Early Highly Effective Therapies Group
-
Environmental Protection Agency (EPA)University of North Carolina, Chapel HillActive, not recruitingCardiovascular Diseases | Respiratory Tract DiseasesUnited States
-
Albert Einstein College of MedicineHealth Resources and Services Administration (HRSA); The New SchoolCompletedDomestic Violence | Child MaltreatmentUnited States
-
University of AarhusCompleted
-
Dayanand Medical College and HospitalCompletedAcute Gastroesophageal Variceal BleedingIndia
-
Superior UniversityActive, not recruiting
-
Peking Union Medical College HospitalUnknown
-
Changhai HospitalFirst People's Hospital of Hangzhou; LanZhou University; Ruijin Hospital; The Second... and other collaboratorsCompletedFasting | Pancreatic Duct Stone | ESWLChina
-
University Hospital Inselspital, BerneCompletedMultiple SclerosisSwitzerland
-
Colorado State UniversityCompletedChronic InsomniaUnited States
-
Hongwei ShiNot yet recruitingPostoperative Recovery | Unilateral Knee Arthroplasty | Postoperative Oral Carbohydrates